Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Verrill · SciRah

Researcher profile · Semantic Scholar

M. Verrill

Share profile

M. Verrill — researcher profile on SciRah

h-index: 28
Works: 124
Citations: 3,569

Most-cited papers

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
L. Smith, V. Cornelius, C. Plummer, G. Levitt +3 more
2010BMC Cancer710 citations Open access
Semantic Scholar
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
A. Jones, M. Barlow, P. Barrett-Lee, P. Canney +5 more
2009British Journal of Cancer228 citations Open access
Semantic Scholar
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
S. Swain, M. Ewer, G. Viale, S. Delaloge +11 more
2017Annals of Oncology227 citations Open access
Semantic Scholar
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
P. Barrett-Lee, J. Dixon, C. Farrell, A. Jones +6 more
2009Annals of Oncology205 citations Open access
Semantic Scholar
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
P. Ellis, P. Barrett-Lee, L. Johnson, D. Cameron +19 more
2009The Lancet184 citations Open access
Semantic Scholar
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.
J. Baselga, M. Zambetti, A. Llombart-Cussac, G. Manikhas +13 more
2009Journal of Clinical Oncology118 citations
Semantic Scholar
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
T. Bachelot, E. Ciruelos, A. Schneeweiss, F. Puglisi +288 more
2019Annals of Oncology108 citations Open access
Semantic Scholar
A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules
A. Boddy, E. Plummer, R. Todd, J. Sludden +7 more
2005Clinical Cancer Research105 citations Open access
Semantic Scholar
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
D. Cameron, J. Morden, P. Canney, G. Velikova +20 more
2017The Lancet Oncology62 citations Open access
Semantic Scholar
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
R. Leonard, M. Lind, C. Twelves, R. Coleman +11 more
2004Journal of the National Cancer Institute56 citations Open access
Semantic Scholar
Hormonal therapy for postmenopausal breast cancer: the science of sequencing
W. Miller, J. Bartlett, P. Canney, M. Verrill
2007Breast Cancer Research and Treatment50 citations Open access
Semantic Scholar
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
J. Gligorov, B. Ataseven, M. Verrill, M. de Laurentiis +6 more
2017European Journal of Cancer45 citations Open access
Semantic Scholar
Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC)
M. Verrill, J. Lee, D. Cameron, R. Agrawal +6 more
200745 citations
Semantic Scholar
Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma
D. Austin, Rebecca H. Maier, Nasima Akhter, Mohammad Sayari +29 more
2024JACC CardioOncology42 citations Open access
Semantic Scholar
Chemotherapy for early-stage breast cancer: a brief history
M. Verrill
2009British Journal of Cancer42 citations Open access
Semantic Scholar
Neuropsychological functioning following systemic treatment in women treated for breast cancer: a review.
R. Morse, Jacqueline Rodgers, M. Verrill, K. Kendell
2003European Journal of Cancer42 citations Open access
Semantic Scholar
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).
S. Chua, I. Smith, R. A'Hern, G. Coombes +11 more
2005Annals of Oncology41 citations Open access
Semantic Scholar
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy
D. Jamieson, N. Cresti, J. Bray, J. Sludden +7 more
2011Pharmacogenetics & Genomics38 citations Open access
Semantic Scholar
Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil
D. Jamieson, J. Lee, N. Cresti, Rosanna K. Jackson +4 more
2014Cancer Chemotherapy and Pharmacology36 citations Open access
Semantic Scholar
Capecitabine and vinorelbine in metastatic breast cancer.
A. Chan, M. Verrill
2009European Journal of Cancer33 citations Open access
Semantic Scholar
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib
J. Horák, J. White, A. Harris, M. Verrill +7 more
2011Cancer Chemotherapy and Pharmacology28 citations Open access
Semantic Scholar
Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma.
D. Jamieson, N. Cresti, M. Verrill, A. Boddy
2009JIM - Journal of Immunological Methods28 citations Open access
Semantic Scholar
Unrecognised severe vitamin D deficiency
J. Sievenpiper, E. McIntyre, M. Verrill, R. Quinton +1 more
2008British medical journal28 citations Open access
Semantic Scholar
Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage
M. Verrill, A. Wardley, Jenny Retzler, Adam B. Smith +5 more
2020Health and Quality of Life Outcomes26 citations Open access
Semantic Scholar
A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer
A. Llombart-Cussac, Miguel Martín, N. Harbeck, R. Anghel +9 more
2007Clinical Cancer Research26 citations Open access
Semantic Scholar
Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study
S. El Badri, B. Tahir, K. Balachandran, P. Bezecny +17 more
2021Breast25 citations Open access
Semantic Scholar
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
C. Dang, M. Ewer, S. Delaloge, J. Ferrero +10 more
2022Cancers22 citations Open access
Semantic Scholar
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer
A. Urruticoechea, C. Archer, La Assersohn, R. Gregory +5 more
2005British Journal of Cancer21 citations Open access
Semantic Scholar
Rare, germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis.
R. A. Speight, A. Nicolle, S. Needham, M. Verrill +2 more
2013Journal of Clinical Oncology19 citations
Semantic Scholar
Desmoplastic small round-cell tumor of the pancreas.
Albiruni Ryan, A. Razak, J. Graham, A. Benson +3 more
2007Journal of Clinical Oncology18 citations
Semantic Scholar
Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study
D. Serin, M. Verrill, A. Jones, T. Delozier +5 more
2005British Journal of Cancer18 citations Open access
Semantic Scholar
Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer.
N. Cresti, J. Lee, E. Rourke, D. Televantou +3 more
2016European Journal of Cancer17 citations
Semantic Scholar
A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies
R. Plummer, P. Woll, D. Fyfe, A. Boddy +6 more
2008Clinical Cancer Research16 citations Open access
Semantic Scholar
Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019)
D. Cameron, P. Barrett-Lee, P. Canney, J. Banerji +16 more
201215 citations
Semantic Scholar
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program
C. Palmieri, A. Musson, C. Harper-wynne, D. Wheatley +9 more
2023British Journal of Cancer13 citations Open access
Semantic Scholar
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.
K. Jung, B. Ataseven, M. Verrill, X. Pivot +6 more
2018The Oncologist13 citations Open access
Semantic Scholar
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
G. Velikova, J. Morden, J. Haviland, C. Emery +13 more
2023The Lancet Oncology11 citations Open access
Semantic Scholar
The rise of oncology biosimilars: from process to promise.
M. Verrill, P. Declerck, S. Loibl, J. Lee +1 more
2019Future Oncology11 citations Open access
Semantic Scholar
Combination Therapy With Ixabepilone Plus Capecitabine Is Effective in ER/PR/HER2-Negative Breast Cancer Resistant to Anthracyclines and Taxanes
H. Rugol, M. Piontek, I. Reeb, E. Thomas +5 more
200811 citations
Semantic Scholar
440 Superiority of tandem high-dose (HDC) over conventionally-dosed chemotherapy(CDC) in patients (Pts) with metastatic breast cancer (MBC): Updated results of the international randomised breast cancer dose-intensity study (IBDIS)
J. Crown, S. Leyvraz, M. Verrill, V. Guillém +6 more
200310 citations
Semantic Scholar
Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.
D. Jamieson, N. Sunter, S. Muro, Lucie Pouché +7 more
2017European Journal of Cancer9 citations Open access
Semantic Scholar
HER2 testing in patients with breast cancer
J. Dixon, V. Wilson, M. Verrill, W. Symmans
2012British medical journal9 citations
Semantic Scholar
Phase II, open label study of SB-715992 (Ispinesib) in subjects with advanced or metastatic breast cancer
K. Miller, C. Ng, P. Ang, A. Brufsky +12 more
20059 citations
Semantic Scholar
Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma.
V. Hess, M. Verrill, C. C. Bomphray, M. Vaughan +2 more
2003Annals of Oncology9 citations Open access
Semantic Scholar
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer
A. Bahl, W. Wilson, J. Ball, E. Renninson +25 more
2022Breast8 citations Open access
Semantic Scholar
Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT)
R. Maier, C. Plummer, A. Kasim, N. Akhter +15 more
2022BMJ Open7 citations Open access
Semantic Scholar
Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors
M. Verrill, A. Boddy, R. Todd, J. Sludden +5 more
20037 citations
Semantic Scholar
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer
S. Holt, M. Verrill, L. Pettit, A. Rigg +11 more
2024British Journal of Cancer6 citations Open access
Semantic Scholar
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
S. Gennatas, Florence E Chamberlain, T. Carter, S. Slater +14 more
2020Clinical Sarcoma Research6 citations Open access
Semantic Scholar
Rationale and design of a UK database for a rare cancer type: the GEM Registry for gastrointestinal stromal tumours
V. Bulusu, J. Fullarton, M. Leahy, C. Morgan +6 more
2013British Journal of Cancer6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Wardley×10
Invite
A. Wardley — researcher profile on SciRah
A. Boddy×8
Invite
A. Boddy — researcher profile on SciRah
N. Cresti×7
Invite
N. Cresti — researcher profile on SciRah
P. Barrett-Lee×6
Invite
P. Barrett-Lee — researcher profile on SciRah

×5

Invite

P. Canney — researcher profile on SciRah

Invite

J. Sludden — researcher profile on SciRah

Invite

M. Griffin — researcher profile on SciRah

Invite

D. Jamieson — researcher profile on SciRah

Invite

D. Cameron — researcher profile on SciRah

Invite

J. Bliss — researcher profile on SciRah

Invite

C. Plummer — researcher profile on SciRah

Invite

R. Leonard — researcher profile on SciRah